Pacific Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacific Biosciences (PACB).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

6Buy

5Hold

1Sell

Consensus RatingNeutral# Analysts12Avg. Consensus PT$2Upside to Avg. PT-19.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	UBS	Doug Schenkel	Assumes	Neutral	$2→$1
May 11, 2026	Barclays	Luke Sergott	PT Raise	Underweight	$1→$2
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Underweight	$2→$1
Mar 6, 2026	Barclays	Luke Sergott	Downgrade	Equal-Weight→Underweight	$2→$2
Dec 15, 2025	Barclays	Luke Sergott	PT Raise	Equal-Weight	$2→$2
Nov 11, 2025	Piper Sandler	David Westenberg	PT Raise	Neutral	$2→$2
Nov 10, 2025	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$2→$2
Aug 11, 2025	Piper Sandler	David Westenberg	PT Raise	Neutral	$1→$2
Jun 25, 2025	Barclays	Luke Sergott	PT Cut	Equal-Weight	$2→$2
May 15, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$2→$1
May 15, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$2
Apr 10, 2025	Canaccord Genuity	Kyle Mikson	Maintained	Buy	$3
Mar 25, 2025	Scotiabank	Sung Ji Nam	PT Cut	Sector Outperform	$6→$2
Feb 20, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$3→$2
Feb 18, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$2→$2
Feb 18, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$3
Feb 14, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$3
Jan 23, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$2→$2
Nov 11, 2024	UBS	John Sourbeer	Downgrade	Buy→Neutral	$2
Nov 11, 2024	Scotiabank	Sung Ji Nam	PT Cut	Sector Outperform	$7→$6

Analyst Ratings News

PRO
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.

Benzinga Newsdesk

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.

Benzinga Newsdesk

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.

Benzinga Newsdesk

Pacific Biosciences of California Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Pacific Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

People Also Watch

People Also Watch

Pacific Biosciences of California Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Pacific Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

PROBarclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

PROBarclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PROBarclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

PROPiper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

PROStephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

People Also Watch

People Also Watch

PRO
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2